NAMSA, a Medtech testing, clinical, and regulatory consulting firm, has entered into a definitive agreement to acquire the U.S. medical device testing operations of WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical and life science industries.

“We are extremely pleased to announce our agreement with WuXi AppTec, as it enables us to expand our portfolio of clinical research and testing solutions for clients,” remarked André-Michel Ballester, NAMSA CEO. “NAMSA and WuXi AppTec’s Medical Device Testing Operations have different areas of expertise but serve the same client base and will enhance the client experience by combining capabilities. Together, we look forward to accelerating Medtech innovation and helping Sponsors deliver life-saving medical technology throughout the world,” concluded Ballester.

The agreement includes WuXi AppTec facilities in Minnesota and Georgia, which will now be owned by NAMSA. Both companies will work for a smooth transition for employees and customers.

NAMSA’s strategic outsourcing and comprehensive in-house services help Medtech innovators mitigate risk, shorten time to market, and enhance stakeholder value.

NAMSA is owned by ARCHIMED. The acquisition of WuXi AppTec’s U.S. Medical Device Testing Operations is the 9th acquisition by NAMSA since becoming an ARCHIMED company.